Story
Novo Nordisk Seeks Approval for Oral Wegovy in China, Escalating Rivalry with Eli Lilly

Novo Nordisk (NVO) confirmed on Thursday that its application to market an oral version of its weight-loss drug Wegovy has been accepted for review by China’s drug regulator. The move marks a critical step in the company's strategy to capture a larger share of the rapidly growing Chinese market for obesity treatments.
Race for a Lucrative Market
The filing intensifies the competition between Novo Nordisk and its primary rival, Eli Lilly (LLY), in the world's second-largest pharmaceutical market. Both companies are vying for dominance in the GLP-1 drug class, which mimics a gut hormone to suppress appetite and regulate blood sugar.
China presents a significant commercial opportunity, with the country's National Health Commission projecting that the rate of overweight or obese people could exceed 65% by 2030. Drugmakers believe that a daily pill could significantly expand the market by attracting patients who are hesitant to use the current standard of once-weekly injections.
AdCompetitive Landscape
Novo Nordisk's move follows a similar filing by its competitor. Eli Lilly submitted a marketing application to Chinese regulators for its own oral GLP-1 drug, orforglipron, at the end of 2025, according to a company statement in March.
Both companies have already secured approvals for their oral medications in other major markets. Novo Nordisk launched its Wegovy pill in the United States this year after receiving early approval, while Eli Lilly secured U.S. approval for orforglipron in April. The competition in China also includes other players like Pfizer and local firm Innovent Biologics, which are developing their own injectable GLP-1 treatments.
Read next
More on Stocks
FTC Orders Walmart, Uber, Delta to Disclose Data on Personalized Pricing
The U.S. Federal Trade Commission is demanding nine major companies, including leading retail, travel, and gig economy firms, to provide information on how they use consumer data for setting individual prices and wages.

Google Launches Gemini 4 Carbon AI Model to Bolster Cybersecurity Capabilities
Alphabet's Google has unveiled Gemini 4 Carbon, its latest AI model specifically designed for advanced cybersecurity tasks like vulnerability detection and secure code generation. The launch escalates competition with rivals OpenAI and Anthropic in the enterprise AI market.

Oracle Shares Surge After Unveiling $225 Billion Revenue Target for 2030
Oracle stock rose sharply after the company presented a long-term financial outlook targeting at least $225 billion in annual revenue by fiscal 2030, driven by its expanding AI infrastructure business.

DOJ Scrutinizes Nvidia's $12.9B Hugging Face Deal Amid Broader Antitrust Probe, Sources Say
The U.S. Department of Justice is reportedly examining Nvidia's planned $12.93 billion acquisition of AI platform Hugging Face as part of a wider, ongoing antitrust investigation into the chipmaker's market conduct.